IgG and IgA MGUS paraproteinaemic neuropathy
Evidence-based neurology checklist on igg and iga mgus paraproteinaemic neuropathy: Criteria for MGUS Monoclonal component ≤ 30g/L Bence Jones protein (BJP) ≤ 1g/24 hours <10% bone marrow infiltration No lytic bone lesions No evolution to myeloma or other lymphoproliferative disease within 12…
Criteria for MGUS
- Monoclonal component ≤ 30g/L
- Bence Jones protein (BJP) ≤ 1g/24 hours
- <10% bone marrow infiltration
- No lytic bone lesions
- No evolution to myeloma or other lymphoproliferative disease within 12 months
- No anaemia
- No hypercalcaemia
- No chronic renal failure
MGUS neuropathy types
Treatment: limited evidence
Acronyms
References
- Joint Task Force of the EFNS and the PNS. European Federation of Neurological Societies/Peripheral Nerve Society Guideline on management of paraproteinaemic demyelinating neuropathies. Report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society. J Peripher Nerve Syst 2006; 11:9-19.
- Dalakas MC. Pathogenesis and treatment of anti-MAG neuropathy. Curr Treat Options Neurology 2010; 12:71-83.
- Gorson KC, Ropper AH. Axonal neuropathy associated with monoclonal gammopathy of undetermined significance. JNNP 1997; 63:163-168.
- Allen D, Lunn MP, Niermeijer J, Nobile-Orizo E. Treatment of IgG and IgA paraproteinaemic neuropathy (review). Cochrane Database of Systematic Reviews 2007; Issue 1. Art. No.: CD005376.
